A world-renowned physician and entrepreneur, Lindsay Rosenwald has
served the medical profession for over 30 years. In that time, Lindsay
Rosenwald has achieved success in a wide array of services including venture capital,
direct investing, asset management and investment banking within the field of
life sciences and biotechnology.
Most notably, Lindsay Rosenwald has
been a significant creator of development-stage biotechnology companies. Throughout his professional career,
Lindsay Rosenwald has overseen the development of more than 100 licensed
clinical-stage medicines. A number of these drugs have earned approval from the
U.S. Food and Drug Administration and foreign countries. One medicine in
particular was to treat acute promyelocytic leukemia, which has since cured
several thousands of incurable patients in the past decade. Under the guidance
of Lindsay Rosenwald, the medicine has marked a dramatic shift in how the
disease will be treated in the future.
Another cancer medicine formulated under the leadership of Lindsay Rosenwald is a prostate cancer drug called abiraterone acetate. The company led by Lindsay Rosenwald that developed this drug became the first of its kind to be acquired for around $1 billion after the completion of just a single phase 2 study when Johnson & Johnson took ownership of the company in a short-term merger. Other drugs approved during the career of Lindsay Rosenwald include drugs approved for treatment of diseases such as schizophrenia, influenza, fibromyalgia, infant respiratory distress syndrome, and obesity.
After graduating from southeast Pennsylvania’s Abington Senior High School in 1973, Lindsay Rosenwald matriculated at Pennsylvania State University. There, Lindsay Rosenwald received a bachelor’s degree in finance and economics, graduating a member of Beta Gamma Sigma, an international honor society.
Beginning his work in the health-care industry in 1977 as an
independent management consultant, Lindsay Rosenwald eventually entered the
prestigious School of Medicine at Temple University in Philadelphia. Upon
completing his degree at Temple in 1983, Lindsay Rosenwald served as an intern
with Abington Medical Hospital. At Abington, he built a private medical
practice from the ground up, maintaining it until 1986. Then Lindsay Rosenwald
pursued his dream of relocating to Wall Street and working as a
physician/financial analyst. At the time, he was one of the few individuals
with concentrations in both of these specialties.
As a vital member of the Columbia Presbyterian Health Sciences Advisory Council, Lindsay Rosenwald has lent his time and expertise to the organization. In 1992, Lindsay Rosenwald was as a NASD-member dealer. Lindsay Rosenwald received acknowledgment for his significant achievements in the medical industry in 2002 when Genetic Engineering News ranked him first on its annual list of 100 Molecular Millionaires.
In 2009, Lindsay Rosenwald further
enhanced his reputation in the health-care community by founding an investment partnership. This revolutionary company specialized in financial investment in health care and
Lindsay Rosenwald is the creator and director of the Rosenwald Foundation, a renowned nonprofit organization in the medical community. Through the Rosenwald Foundation, Lindsay Rosenwald supports a host of scientific and medical institutions.
- Temple University School of MedicineMedicine
- Pennsylvania State UniversityFinance